Healthcare Resource Use and Costs Associated With Herpes Zoster Among Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study Clinical Practice Research Datalink 2012-2019
Author(s)
Marie Libérée Nishimwe, MSc1, Abda Mahmood, BSc (Hons), MSc, PhD2, Yasmeeta Vekria, BSc (Hons)3, Manjit Hunjan, BA, MSc, MBA, PhD3, Driss Oraichi, PhD4, Karabo Keapoletswe, MSc5, Bhagyalakshmi Chengat Prakashbabu, PhD5, Spyros Paparrodopoulos, MSc6, Simeon Stavrev, BSc7, Lori Cirneanu, BSc, MSc5, Claire O'Reilly, Ms, MPharm3, Sarah Lay-Flurrie, BSc (Hons), MSc, DPhil (Oxon)5, Valeria Saglimbene, PhD5, Inga Posiuniene, MD2, Susan Farrow, MA3, Boriana Guimicheva, MDRes3, Chris Raspin, MSc3, Alen Marijam, PharmD2.
1GSK, Rueil Malmaison, France, 2GSK, Wavre, Belgium, 3GSK, London, United Kingdom, 4GSK, Rockville, MD, USA, 5IQVIA Ltd, London, United Kingdom, 6IQVIA Ltd, Athens, Greece, 7IQVIA Ltd, Sofia, Bulgaria.
1GSK, Rueil Malmaison, France, 2GSK, Wavre, Belgium, 3GSK, London, United Kingdom, 4GSK, Rockville, MD, USA, 5IQVIA Ltd, London, United Kingdom, 6IQVIA Ltd, Athens, Greece, 7IQVIA Ltd, Sofia, Bulgaria.
OBJECTIVES: Postherpetic neuralgia often follows herpes zoster (HZ). HZ imposes significant healthcare burden. Granular data on healthcare resource use (HCRU) and costs associated with HZ are limited.
METHODS: A retrospective cohort study utilised the Clinical Practice Research Datalink linked to Hospital Episodes Statistics, and identified immunocompromised (IC) >18 year-old (YO) adults in England (with any of these conditions: haematological malignancies, haematopoietic stem cell transplantation, solid organ transplant/malignancies, human immunodeficiency virus, autoimmune diseases) and those without these conditions (IC-free), from 2012 to 2018. They were followed until 2019. All-cause HCRU and costs (in 2023 Pound sterling [£]) were estimated (per 1,000 person-years [95% confidence intervals]) from 7 days before to 365 days after HZ, by HCRU type (HZ common prescriptions, inpatient admissions, general practitioner [GP], accident and emergency, outpatient visits), immunocompromising condition, and age.
RESULTS: Of 1,764,900 IC and 12,867,750 IC-free adults, 54,574 IC (3.09%) and 182,707 IC-free (1.42%) developed HZ, respectively. Prescriptions and GP visits represented the highest overall HCRU rates across IC/IC-free adults. Age-specific prescription rates were higher in IC than IC-free: 7,265 (7,202-7,328) vs. 3,346 (3,331-3,362) in 18-49 YOs and 18,820 (18,731-18,909) vs. 15,455 (15,396-15,514) in ≥80 YOs, respectively. GP visits rates were higher in IC than IC-free: 7,362 (7,298-7,425) vs. 5,232 (5,213-5,251) in 18-49 YOs and 13,056 (12,982-13,131) vs. 10,807 (10,758-10,857) in ≥80 YOs, respectively. Inpatient admissions incurred the highest overall costs across IC/IC-free; costs were higher in IC than IC-free across age groups: £1,247,275 (£1,246,451-£1,248,100) vs. £325,118 (£324,968-£325,269) in 18-49 YOs and £3,642,731 (£3,641,491-£3,643,970) vs. £2,744,723 (£2,743,934-£2,745,511) in ≥80 YOs, respectively. All types of HCRU and associated costs had similar patterns.
CONCLUSIONS: IC adults had higher HZ-associated HCRU and costs than IC-free adults. Results could be used to evaluate the economic and healthcare value of prevention in alleviating the burden of HZ in these populations.
METHODS: A retrospective cohort study utilised the Clinical Practice Research Datalink linked to Hospital Episodes Statistics, and identified immunocompromised (IC) >18 year-old (YO) adults in England (with any of these conditions: haematological malignancies, haematopoietic stem cell transplantation, solid organ transplant/malignancies, human immunodeficiency virus, autoimmune diseases) and those without these conditions (IC-free), from 2012 to 2018. They were followed until 2019. All-cause HCRU and costs (in 2023 Pound sterling [£]) were estimated (per 1,000 person-years [95% confidence intervals]) from 7 days before to 365 days after HZ, by HCRU type (HZ common prescriptions, inpatient admissions, general practitioner [GP], accident and emergency, outpatient visits), immunocompromising condition, and age.
RESULTS: Of 1,764,900 IC and 12,867,750 IC-free adults, 54,574 IC (3.09%) and 182,707 IC-free (1.42%) developed HZ, respectively. Prescriptions and GP visits represented the highest overall HCRU rates across IC/IC-free adults. Age-specific prescription rates were higher in IC than IC-free: 7,265 (7,202-7,328) vs. 3,346 (3,331-3,362) in 18-49 YOs and 18,820 (18,731-18,909) vs. 15,455 (15,396-15,514) in ≥80 YOs, respectively. GP visits rates were higher in IC than IC-free: 7,362 (7,298-7,425) vs. 5,232 (5,213-5,251) in 18-49 YOs and 13,056 (12,982-13,131) vs. 10,807 (10,758-10,857) in ≥80 YOs, respectively. Inpatient admissions incurred the highest overall costs across IC/IC-free; costs were higher in IC than IC-free across age groups: £1,247,275 (£1,246,451-£1,248,100) vs. £325,118 (£324,968-£325,269) in 18-49 YOs and £3,642,731 (£3,641,491-£3,643,970) vs. £2,744,723 (£2,743,934-£2,745,511) in ≥80 YOs, respectively. All types of HCRU and associated costs had similar patterns.
CONCLUSIONS: IC adults had higher HZ-associated HCRU and costs than IC-free adults. Results could be used to evaluate the economic and healthcare value of prevention in alleviating the burden of HZ in these populations.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE504
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin), Vaccines